A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Cancer

Status:

Closed to Accrual

III

Phase

Adjuvant

Line of Therapy

Advanced / Metastatic

Disease Stage

Biomarker(s)

PD-1, PD-L1, EGFR, ALK

Investigational

Product

Durvalumab (MEDI4736)

Anti-PD-L1 Monoclonal Antibody (i.v.)

Treatment Arms

o Experimental: MEDI4736

o Placebo Comparator: Placebo